Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

Early Phase 1

Completed

• Conditions: Liver Transplant Disorder
• Interventions: Other: 0.9% normal saline; Drug: Mannitol

• Registration Number: NCT05277623
• Lead Sponsor: Ain Shams University

Brief Summary

Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-03-04
• Study First Submitted QC: 2022-03-04
• Study First Posted: 2022-03-14
• Study Start: 2022-04-04
• Primary Completion: 2022-11-05
• Study Completion: 2022-12-10
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-15
• Last Update Posted: 2023-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• patients with end-stage liver disease who will undergo living donor transplantation.

Exclusion Criteria

• Patients with a history of portopulmonary hypertension.
• Hepatopulmonary syndrome.
• Cirrhotic cardiomyopathy.
• Hepatorenal syndrome types 1 and 2.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control group	0.9% normal saline	-
mannitol group	Mannitol	-

Primary Outcome Measures

Name	Time	Method
mean arterial blood pressure	one hour after reperfusion	postreperfusion mean blood pressure

Trial Locations

Locations (1)

Medicine Ain Shams University; 🇪🇬 Cairo, Egypt